Drug Search Results
More Filters [+]

DB-1310

Alternative Names: DB-1310, DB 1310, DB1310
Latest Update: 2024-09-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ERBB3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: DualityBio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DB-1310

Countries in Clinic: China, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Breast Cancer|Esophageal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DB-1310-O-1001

P2

Recruiting

Prostate Cancer|Esophageal Cancer|Non-Small-Cell Lung Cancer|Breast Cancer|Head and Neck Cancer|Squamous Cell Carcinoma

2026-08-31

Recent News Events

Date

Type

Title